Elektrofi receives contract under the Defense Health Agency

By The Science Advisory Board staff writers

March 1, 2022 -- Elektrofi has entered into a contract with the Defense Health Agency Small Business Innovation Research Program within the U.S. Department of Defense to explore the company's platform formulation technology for the delivery of prefilled, high-dose formulations for the rapid deployment of antibody treatments for COVID-19 and pandemic preparation.

Elektrofi's platform formulation technology aims to provide an alternative to current delivery methods for antibody treatments, which require intravenous administration in a healthcare setting. Under the contract, Elektrofi will use its technology to pioneer COVID-19 antibody therapies for self-administration at home, widening the potential distribution for these essential medicines.

Elektrofi may be eligible to extend this funding through an enhancement program that requires matched funds from an outside funding source. Elektrofi will evaluate candidate industry partners with promising antibody or antibody cocktail therapies for the treatment of COVID-19. While under the contract, Elektrofi's high-concentration formulation technology will be applied to the selected partner's antibody product to formulate, manufacture, and conduct investigational new drug (IND)-enabling studies.

Elektrofi has developed proprietary microparticle technology that enables patient-friendly, small-volume injections for monoclonal antibodies, therapeutic proteins, and other large molecule drugs that are of growing importance to human health. It has the potential to drive significant change in the treatment landscape for patients across a variety of disease areas and indications.

Elektrofi is a biotechnology company focused on drug formulation and delivery innovations.

Elektrofi, Takeda partner to advance plasma protein therapeutics
Biotechnology firm Elektrofi and Takeda Pharmaceuticals have partnered to advance high-concentration, low-viscosity protein therapeutics.

Copyright © 2022 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter